EUCRU (Eucrates Biomedical Acquisition) Price-to-Operating-Cash-Flow : (As of Dec. 15, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Price-to-Operating-Cash-Flow?

As of today (2024-12-15), Eucrates Biomedical Acquisition's share price is $10.02. Eucrates Biomedical Acquisition's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00. Hence, Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 3 years, Eucrates Biomedical Acquisition's highest Price-to-Operating-Cash-Flow Ratio was 135.34. The lowest was 0.00. And the median was 0.00.

EUCRU's Price-to-Operating-Cash-Flow is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 33.275
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Eucrates Biomedical Acquisition's Cash Flow from Operations per share for the three months ended in Dec. 2022 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00.

Eucrates Biomedical Acquisition Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Price-to-Operating-Cash-Flow Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Price-to-Operating-Cash-Flow

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow falls into.

Eucrates Biomedical Acquisition Price-to-Operating-Cash-Flow Calculation

Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	10.02	/
	=

Eucrates Biomedical Acquisition's Share Price of today is $10.02.
Eucrates Biomedical Acquisition's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Eucrates Biomedical Acquisition Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021